Abstract:Abstract Background The p38 alpha mitogen‐activated protein kinase (p38α) pathway is linked to both innate and adaptive immune responses, and is currently under investigation as a target for drug development in the context of Alzheimer’s disease (AD) and other conditions with neuroinflammatory dysfunction (Asih et al., 2020). Preclinical data indicates that p38α inhibition can protect against AD‐associated neuropathology, although the cellular mechanisms and signaling pathways that underlie these effects have not been fully elucidated. Evidence suggests that inhibition of p38α may provide benefit by modulating microglial‐associated neuroinflammatory processes that contribute to the development of AD pathology. The present study tests this hypothesis by assessing early‐stage pathological changes in AD model mice following microglial‐specific knock out (KO) of p38α. Methods KO of p38α in microglia was accomplished in 5‐month‐old C57BL/6J wild‐type and amyloidogenic AD model (APPswe/PS1dE9) mice using a tamoxifen‐inducible Cre/loxP system under control of the Cx3Cr1 promoter. Animals underwent behavioral assessment on the open field test at 7.5 months of age and on the radial arm water maze test at 11 months of age, followed by collection of cortical and hippocampal tissues. Other endpoint measures included quantification of proinflammatory cytokines, assessment of amyloid burden and plaque deposition, and characterization of microglia‐plaque dynamics using a combination of ELISA, immunohistochemical, and immunofluorescent techniques. Results Suppression of microglial p38α did not alter behavioral outcomes, proinflammatory cytokine levels, or overall amyloid plaque burden, but did significantly increase hippocampal levels of soluble Aβ42 and reduced hippocampal colocalization of Iba1 and 6E10 in a subset of microglia in close proximity to plaques. Conclusion This work suggests that rather than reducing inflammation per se, microglial p38α inhibition in the context of early AD‐type amyloid pathology may alter hippocampal microglia‐plaque interactions. Additionally, these results support future investigations of microglial p38α signaling at different stages of disease, as well as the potential relationship between p38α and phagocytic processes in this particular cell‐type. Funding : This work is supported by the National Institutes of Health (RF1 AG064859; F32 AG058456; T32 AG057461).

Involvement of P38MAPK Activation by NMDA Receptors and Non-Nmda Receptors in Amyloid-Β Peptide-Induced Neuronal Loss in Rat Hippocampal CA1 and CA3 Subfields

MLK3‐MKK3/6‐P38MAPK Cascades Following N‐methyl‐D‐aspartate Receptor Activation Contributes to Amyloid‐β Peptide‐induced Apoptosis in SH‐SY5Y Cells

A Brief Ischemic Postconditioning Protects Against Amyloid-β Peptide Neurotoxicity by Downregulating MLK3-MKK3/6-P38MAPK Signal in Rat Hippocampus.

Oligomerized Abeta25-35 induces increased tyrosine phosphorylation of NMDA receptor subunit 2A in rat hippocampal CA1 subfield.

The P38 Mitogen Activated Protein Kinase Regulates Β-Amyloid Protein Internalization Through the Α7 Nicotinic Acetylcholine Receptor in Mouse Brain.

Oligomerized Aβ25–35 induces increased tyrosine phosphorylation of NMDA receptor subunit 2A in rat hippocampal CA1 subfield

P38 Activation Mediates Amyloid-Beta Cytotoxicity

[Expression of P38mapk in the Hippocampal CA1 Region of Rats with Abeta25-35-induced Alzheimer Disease].

The p38 mitogen-activated protein kinase signaling pathway is involved in regulating low-density lipoprotein receptor-related protein 1-mediated β-amyloid protein internalization in mouse brain

P38 Activation Mediates Amyloid-β Cytotoxicity

p38 MAPK‐mediated loss of nuclear RNase III enzyme Drosha underlies amyloid beta‐induced neuronal stress in Alzheimer's disease

Activation of Α7 Nicotinic Acetylcholine Receptor Alleviates Aβ1-42-induced Neurotoxicity Via Downregulation of P38 and JNK MAPK Signaling Pathways.

P1‐210: DAPK1 IS REQUIRED FOR THE EARLY NEURONAL DAMAGE AND COGNITIVE IMPAIRMENT INDUCED BY Aβ OLIGOMERS

P4‐188: MAPKS SIGNALING PATHWAYS REGULATES THE ACTIVATION OF LRP1 RECEPTOR ON THE INTERNALIZATION OF Aβ <sub>1‐42</sub> AND Aβ <sub>1‐42</sub> ‐INDUCED NEUROTOXICITY

Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyloid‐associated pathology

Time-dependent effect of oligomeric amyloid-β (1-42)-induced hippocampal neurodegeneration in rat model of Alzheimer's disease

[Expression of P38mapk in the Olfactory Bulb of Rats with Alzheimer's Disease].

Involvement of p38 MAPK in Synaptic Function and Dysfunction

Modulation of the MAPKs Pathways Affects Aβ-induced Cognitive Deficits in Alzheimer’s Disease Via Activation of Α7nachr

Different Protection of K252a and N‐acetyl‐L‐cysteine Against Amyloid‐β Peptide–induced Cortical Neuron Apoptosis Involving Inhibition of MLK3–MKK7–JNK3 Signal Cascades

Differential Regulation of N-Methyl-D-Aspartate Receptor Subunits is an Early Event in the Actions of Soluble Amyloid-β(1-40) Oligomers on Hippocampal Neurons.